Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Miller, David S., Filiaci, Virginia L., Mannel, Robert S., Cohn, David E., Matsumoto, Takashi, Tewari, Krishnansu S., DiSilvestro, Paul, Pearl, Michael L., Argenta, Peter A., Powell, Matthew A., Zweizig, Susan L., Warshal, David P., Hanjani, Parviz, Carney, Michael E., Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2020
Témata:
RAPID COMMUNICATIONS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676887/
https://ncbi.nlm.nih.gov/pubmed/33078978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01076
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky